UCB (OTCMKTS:UCBJF) Trading Down 5.9% – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares were down 5.9% on Thursday . The stock traded as low as $248.60 and last traded at $248.60. Approximately 69 shares traded hands during trading, a decline of 90% from the average daily volume of 725 shares. The stock had previously closed at $264.09.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on UCBJF shares. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

UCB Stock Performance

The company’s 50 day moving average price is $276.22 and its two-hundred day moving average price is $291.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.